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ABSTRACT 
Oral route is one of the most popular routes of drug delivery due to its ease of administration, patient compliance, least sterility constraints and 
flexible design of dosage form. The aim of present investigation was to develop matrix tablets of atenolol using different polymers. Atenolol 
matrix tablets were prepared by direct compression and wet granulation method using different polymers. All the formulations were evaluated 
for weight variation, thickness, hardness, friability and dissolution. Tablets of atenolol were prepared utilizing natural polymer chitosan. The 
formulation F-2 contained chitosan which might have sustained the release since it is also known for its polymeric sustaining effect. The 
formulation F-2 gave 89.57±0.24% of the drug release in 12 hrs of study.  
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1. INTRODUCTION 
Oral route is one of the most popular routes of drug delivery 
due to its ease of administration, patient compliance, least 
sterility constraints and flexible design of dosage form 1. 
Over 90% of the formulations manufactured today are 
ingested orally. This shows that this class of formulation in 
the most popular worldwide and the major attention of the 
researcher in toward this direction. With advanced in 
technology and increase in awareness, toward modification 
in standard tablets is done to achieve better acceptability as 
well as bioavailability because of which newer and more 
efficient tablet dosage forms are being developed. The main 
reasons behind formulation of different type of the tablets 
are to create a delivery system that is relatively simple and 
in expensive to manufacture, provide the dosage form that is 
convenient from patient’s perspective and utilize an 
approach that is unlikely to add complexity during 
regulatory approval process. To understand each dosage 
form, tablets here are classified by their route of 
administration and by the type of drug delivery system they 
represent within route 2-8. 
Tablet ingested orally are meant to be swallowed intact 
along with sufficient quantity of the potable water. 
Exceptions are chewable tablet and oral dispersible tablets. 
Standard compressed tablets this class includes tablets like, 
multiple compressed tablets, compression coated tablets, 
layered tablets, modified released tablets etc 9-12. 
In the present work, Atenolol will be utilized with a natural 
polymer chitosan and HPMC to formulate tablets against 
hyperglycemia. Atenolol has low bioavailability as is evident 
from the available literature although it is freely soluble in 
water, because it is a BCS class III drug which is known for 
their high solubility but low permeability and hence low 
bioavailability. Natural polymer chitosan is known for its 
permeability enhancement through mucosal membrane and 
will enhance drug absorption. This in turn will reduce the 
dose size and dosing frequency and subsequently will result 
in result in efficient drug therapy and patient compliance 13-
20.
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2. EXPERIMENTAL WORK 
2.1. Drug profile 
Name Atenolol 
Description A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, 
but without a negative inotropic effect. 
Structure 
 
 
Brand name mixtures 
Categories  Antihypertensive Agents 
 Adrenergic Agents 
 Adrenergic beta-Antagonists 
 Sympatholytics 
 Antiarrhythmic Agents 
 Anti-Arrhythmia Agents 
CAS number 29122-68-7 
Chemical Formula C14H22N2O3 
IUPAC Name 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide 
Taxonomy 
Kingdom Organic 
Classes  Phenols and Derivatives 
 Ethers 
 Phenethylamines 
 Anisoles 
Substructures  Hydroxy Compounds 
 Aliphatic and Aryl Amines 
 Phenols and Derivatives 
 Amino Ketones 
 Ethers 
 Benzene and Derivatives 
 Carbamates and Derivatives 
 Amino Alcohols 
 Phenethylamines 
 Aromatic compounds 
 Anisoles 
 Carboxamides and Derivatives 
 Carboxylic Acids and Derivatives 
 Alcohols and Polyols 
 Phenyl Esters 
Pharmacology 
Indication For the management of hypertension and long-term management of patients with angina pectoris 
Pharmacodynamics Atenolol, a competitive beta(1)-selective adrenergic antagonist, has the lowest lipid solubility of this 
drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it 
does not have intrinsic sympathomimetic properties or membrane-stabilizing activity. Atenolol is used 
alone or with chlorthalidone in the management of hypertension and edema. 
Mechanism of action Like metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines 
for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting 
sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and 
diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also 
competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles. 
Absorption Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being 
excreted unchanged in the feces. 
Protein binding Plasma protein binding is 6-16% 
Metabolism Hepatic (minimal) 
Route of elimination Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being 
excreted unchanged in the feces. Unlike propranolol or metoprolol, but like nadolol, atenolol undergoes 
little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal 
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excretion. 
Half life 6-7 hours 
Toxicity LD50=2000-3000 mg/kg(orally in mice). Symptoms of an atenolol overdose include a slow heart beat, 
shortness of breath, fainting, dizziness, weakness, confusion, nausea, and vomiting. 
Properties 
State Solid 
Melting point 146-148Oc 
 
Experimental 
Properties 
 
Property Value Source 
water solubility 13.5 mg/mL PhysProp 
logP 0.5 PhysProp 
Caco2 permeability -6.44 [ADME Research, USCD] BiGG 
 
Drug Interactions 
Food Interactions  Consult your doctor before taking large amounts of Vitamin K  
 (Green leafy vegetables). 
 Take 30-60 minutes before meals, take at the same time each day. 
 
3.  Preformulation Study 
Pre-formulation may be described as a phase the research and 
development process where the formulation scientist 
characterizes the physical, chemical and mechanical 
properties of new drug substances, in order to develop stable, 
safe and effective dosage forms [21-25]. Ideally the pre-
formulation phase begins early in the discovery process such 
that the appropriate physical and chemical data is available to 
aid the selection of the new chemical entities that enter the 
development process Table 1 [26-33]. 
3.1 Organoleptic property: 
Table 1: Description of the drug (Atenolol). 
  S NO.    Description Atenolol drug 
     1    State Solid 
     2    Colour White  
     3    Odour Odourless 
     4           Texture Amorphous powder 
 
3.2  Solubility studies: 
Determination of solubility of drug by visual observation. An 
excess quantity of Atenolol was taken separately and add in 
10 ml of different solutions. These solutions were shaken well 
for few minutes. Then the solubility was observed and 
observations are shown in the Table 2- 
Table 2: Solubility studies of drug in different solvents. 
 S NO. Solvents Solubility of Atenolol 
    1 Water Freely soluble 
    2 Methanol Soluble 
    3 Acetone  Insoluble 
    4 Alcohol  Sparingly soluble 
    5  Methylene chloride  Practically insoluble 
 
3.3 Melting point: 
Melting point of the drug was determined by the capillary 
method using melting point apparatus. It can be performed by 
filling of the drug in capillary tube  by  pressing the open end 
gently into pure drug sample and packed by tapping the 
bottom of the capillary on a hard surface  so that the drug 
pack down into the bottom of the tube. The apparatus was 
started and the temperature was noted at which the drug 
method. And dip the thermometer in this liquid paraffin and 
the note the point which drug started melting in the capillary. 
Melting point of drug has been shown in the Table 3. 
Table 3: Melting point of drug 
          Drug     Specification      Observation 
       Atenolol       146-148oC        147-149oC  
 
3.4 Standard calibration curve for Atenolol: 
 Preparation of standard solution:  
10 mg of drug was weighed accurately and transferred to 10 
ml of volumetric flask. Then 0.1N HCL was added to dissolve 
the drug completely. The volume was made up to 10 ml with 
0.1N HCL .The prepared sample was 1000µg/ml. 1ml of above 
solution was then transferred to another 10-ml volumetric 
flask and diluted it upto the mark with 0.1 N HCL. This sample 
was 100µg/ml. Then 1 ml of above solution was then 
transferred to another 10ml volumetric flask and diluted it 
upto the mark with ethanol. This sample was 10µg/ml. Now 
scanned this sample by UV (Figure 1).  
3.5 Standard Calibration Curve 
Preparation of standard calibration curve of Atenolol in HCL 
 Preparation of stock solution  
10 mg of drug was weighed accurately and transferred to 10 
ml of volumetric flask. Then 0.1N HCL was added to dissolve 
the drug completely. The volume was made up to 10 ml with 
0.1N HCL .The prepared sample was 1000µg/ml. 1ml of above 
solution was then transferred to another 10-ml volumetric 
flask and diluted it up to the mark with 0.1 N HCL. This sample 
was 100µg/ml (Figure 1). 
 Preparation of dilution from stock solution 
For the dilution 0.2ml of above stock solution was taken and 
diluted it upto 10ml with 0.1N HCL to get concentration of 2 
µg/ml an in the similar way dilution of 4, 6. 8and 10 µg/ml 
was obtained. The absorbance was measured by UV visible 
spectrophotometer. The absorbance values were plotted 
against concentration (µg/ml) to obtain the standard 
calibration curve Table 4. 
Table 4: Absorbance of different aliquots of Atenolol at 
225nm 
S.NO Concentration (μg/ml) Absorbance 
1 10 0.132 
2 20 0.251 
3 30 0.348 
4 40 0.471 
5 50 0.529 
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Figure 1: Graph showing linearly regressed calibration 
curve of Atenolol 
Formulation of Matrix Tablet: 
Sustained release Matrix Tablet of Atenolol with other 
excipient was prepared by wet granulation method. The 
weight of Atenolol was kept constant in all the prepared tablet 
at 350mg/tablet. Accurately weight quantity of polymer (for 
particular formulation), Atenolol, Lactose were taken in 
mortar and mixed. Starch paste 6% was added to the dry 
blend gradually with constant kneading to ensure a 
homogenous mass (Table 5). 
The Dough mass was passed through a # 14mesh sieve. Then 
granules were dried at 500 and dried granules were lubricated 
with talc and magnesium stearate and compressed into tablet 
using 10mm punches. Each tablet contain 50mg of Atenolol. 
The drug matrix ratio was varied to obtain the matrix tablet of 
polymer concentration. 
During this evaluation, possible interactions with various 
inert ingredients intended for use in final dosage form is also 
considered in the present study. The following data must be 
considered (Goyal et. al., 2009). 
 
Table 5: Preliminary screening of formulation of sustained release layer of Atenolol using natural, hydrophilic and 
hydrophobic polymers 
Ingredients(mg) F1 F2 F3 F4 F5 
Atenolol 50 50 50 50 50 
HPMC 15cps 35 55 75 - - 
Chitosan 70 50 30 25 30 
Gar Gum - - - 45 40 
Mg- Stearate 3.5 3.5 3.5 3.5 3.5 
Lactose 188 188 188 223 223 
Talc 3.5 3.5 3.5 3.5 3.5 
Total 350 350 350 350 350 
 
4. Evaluation of Pre-compression Parameters 
4.1. Angle of repose 
The angle of repose was determined by fixed funnel method. 
A funnel was kept vertically in a stand at a specified height 
above a paper place on a horizontal surface. The funnel was 
closed and a granule was filled in funnel. Then funnel was 
opened to release the granules on the paper to form a 
smooth conical heap. The height and radius of heap was 
measured and the angle of repose was calculated by using 
the following formula (Table 6). 
                                   Ø= tan-1 h/r 
  Where Ø = Angle of repose, h =height of heap and r = radius  
Table 6: Relationship between Angel of repose (Ø) and 
flow properties. 
Angle of repose (Ø) Type of flow 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very Poor 
 
 
4.2. Bulk Density  
A known amount of granules was transferred in to a 25-ml 
measuring cylindrical carefully level the granules without 
compacting and measure the bulk volume.  The bulk density 
was determined by using the formula 
Bulk density = Weight of granules/ bulk volume 
4.3. Tapped Density: 
 Tapped density was determined by digital bulk density 
apparatus. A known amount of granules was transferred into 
the measuring cylinder and tapped up to 100 times and 
measure the tapped volume. The tapped density was 
determined by using the formula. 
Tapped Density = Weight of granules / tapped volume  
4.4. Compressibility Index (Table 7) 
 Compressibility Index=  
[Tapped density- Bulk density/Tapped density] ×100 
  
 
 
y = 0.0116x + 0.008 
R² = 0.9986 
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Table 7: Practical Consideration of Compressibility 
Index 
% Compressibility index Flow 
5-15 Excellent  
12-16 Good  
18-21 Fair to passable 
23-35 Poor 
33-38 Very Poor 
>40 Very 
 
4.5. Hausner’s Ratio (Table 8) 
          Hausner’s Ratio was determine by following formula 
Hausner’s Ratio= Tapped density / Bulk density  
Table 8: Practical Consideration of Hausner’s Ratio 
Hausner’s ratio Flow 
<1.25 Good 
>1.25 Poor 
1.25-1.5 Very poor 
 
4.6. Hardness 
In the measurement of hardness, the crushing strength of the 
tablets is measured. It gives the table breaking force and the 
strength of the physical tablets are represented by the 
hardness. Hardness was measured using a Pfizer hardness 
tester. Hardness to be measured of ten tablets. The V was 
measured in Newton. The average hardness, relative 
standard deviation, standard deviations were reported. The 
hardness of the tablets were measured start and between the 
compression. 
4.7. Weight variation test 
To study weight variation, 20 tablet of each formulation 
were collected randomly during compression and weight 
using an electronic balance to obtain average weight of each 
tablet. Also the individual tablet was weighted. 
Limit: Weight of individual tablet should be in the limit of 
average weight ±5% 
4.8. Friability:  
The test was carried out using ROCHE FRIABILATOR. Ten 
tablets were taken and carefully dedusted prior to testing 
the tablets were weighted accurately, and placed the tablets 
in drum. The drum was allowed to be rotated 100 times, and 
after that the tablet were removed. Removed loose dust from 
the tablets as before, and weighted accurately. 
The % loss was determined by using following formula:  
%Weightloss = Initial Weight-Final Weight 
                      Initial Weight 
    A maximum loss of mass not greater than 1.0%is 
considered acceptable 
4.9. Uniformity of drug content (Table 9) 
Five tablets were weighed individually and powdered. The 
powdered equivalent to average weight of tablet was 
weighed and drug was extracted in 0.1N HCL. Undissolved 
material was filtered out. Fitrate was analysed in uv 
spectrometer at 225nm after suitable dilution. Absorbance 
value was substituted in the equation of standard curve of 
Atenolol determined earlier. 
Drug content was calculated by following formula.
 
Table 9: Evaluation of Precompression parameters 
Parameters F1 F2 F3 F4 F5 
Angle of Repose(n=3)  28.2 28.5 31.1 33.6 35.24 
Bulk Density(n=3) 0.52 0.54 0.56 0.60 0.64 
Tapped density(n=3) 0.60 0.59 0.65 0.70 0.76 
Carss’s Index(%)(n=3) 11.66 12.0 14.47 15.11 16.66 
Hausner’s Ratio(n=3) 1.13 1.14 1.16 1.18 1.2 
Thickness(mm)(n=20) 2.44 2.46 2.51 2.52 2.56 
Friability (%)(n=10) 0.2 0.28 0.31 0.46 0.5 
Weight Variation (%)(n=20) 2.20 2.22 2.26 2.28 2.3 
 
4.10. In- vitro Dissolution Study  
In-vitro drug release study of tablet was performed in USP 
dissolution apparatus type -2 (Paddle). The dissolution test 
was performed using 900 ml of 0.1 N HCL at 37oC. 
0.5 oC with 50 rpm. A sample (3 ml) was withdrawn from the 
dissolution apparatus and volume equivalent to the amount 
of the sample withdrawn was replaced with fresh dissolution 
medium. The sample was filtered and suitable concentration 
with 0.1 N HCL. Absorbance of these solutions was measured 
at 225nm using UV spectrophotometer. Cumulative 
percentage drug dose was calculated using an equation 
obtained from standard curve. 
4.11.  In- Vitro Drug Release Kinetic Study 
 Kinetic model had described drug dissolution from solid 
dosage form were the dissolved amount of drug is a function 
of test time. In order to study the exact mechanism of drug 
release from the tablet, drug release data was analyzed 
according to zero order, first order, Higuchi square root, 
Korsmeyer, Peppas model. The regression coefficient R2 
value nearer to 1 indication the model fitting of the release 
mechanism (Table 10). 
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Table 10: Release kinetic study 
Time % Cumulative Drug Release 
(hr) F1 F2 F3 F4 F5 
0.5 08.23 07.14 07.24 08.23 07.23 
1 12.32 18.23 11.45 10.45 10.45 
1.5 26.23 22.42 24.23 23.76 31.23 
2 38.45 40.32 45.23 44.23 48.23 
3 52.34 54.11 61.21 65.71 50.56 
4 61.23 67.33 68.11 82.34 55.00 
6 70.55 71.13 72.13 83.00 56.00 
8 81.00 85.10 7523 83.21 57.25 
12 83.21 89.57 79.26 83.50 57.85 
 
5. RESULT AND DISCUSSION  
In the matrix tablet, HPMC and chitosan were used as 
retardant materials for sustained release action. 
Preformulation of the drug was carried out with respect to 
different parameters. Drug was separately tested for their 
physicochemical characteristics. Melting point of Atenolol 
was found to be 146-148oC respectively. Similarly solubility 
studies were conducted for the drug in different solvents. It 
was found that the drug was freely soluble in water, soluble 
in methanol, insoluble in acetone, sparingly soluble in 
alcohol and practically insoluble in methylene chloride.  
UV spectroscopy of the drug was also performed and the 
drug was scanned on different wavelengths.  λmax of Atenolol 
was found to be 225 nm. All the values calculated were found 
to be concordant which that of the standard values reported 
in Standard Pharmacopoeial books. It was observed that 
there was no significant shift in the melting point of the drug 
when taken alone or in combination with that of polymer 
used. On the basis of the compatibility studies, it was found 
that drug is compatible with all other excipients selected for 
the study and hence can be used in combination for the 
preparation of the tablets. 
Atenolol sustained release matrix tables were prepared by 
wet granulation method, different formula were designed to 
formulate the tablets which have been mentioned in table 
no.1.5. In the matrix tablet, HPMC were selected as 
retardants material for the sustained released action (more 
than 20% drug released in 1 hrs). Starch past was selected as 
a binder with 6%. Lactose was selected as diluents with 
17.6% and Magnesium stearate was selected as lubrication 
and Talc was selected as a glident. All different formulation 
containing different amount of HPMC, Lactose were 
prepared to formulate the tablets.  
Angle of repose was found to be between 28.2°- 35.24°, 
where some of the blend fell between the specified limit of 
20° - 30° representing good flow. Bulk density was found to 
be between 0.52 – 0.64 g/ml. Tapped density was found to 
be between 0.60 – 0.76 g/ml. Carr’s index (%) was found to 
be in the range of 11.66 – 16.66, all the powder blend are 
well within the specification limit. Hausner’s ratio was found 
to be between 1.13 -1.2. With this the powder blends were 
found to be free flowing material and showed suitability to 
be compressed as tablets of expected weight.  
It was observed that hardness of the all sustained released 
tablets were measured Pfizer hardness tester. The thickness 
of all SR matrix tablets was measured by vernier caliper and 
was ranged between 2.44-2.56. On the basis of the 
parameters viz. weight variation, hardness and friability the 
best formula was selected. F-2 formulation was found to be 
the best formula and hence was taken as the optimized 
formula. Tablets prepared out of formula F-2 represented a 
weight variation of 2.22±0.11, hardness of 5.3±0.32, friability 
of 0.28±0.01. The tablets prepares from lactose as an 
excipient acquired a sticky nature and hence were not taken 
for consideration for further study.  
The tablets prepared out of the optimized formula were 
taken into consideration for further in vitro dissolution drug 
release study.  In- vitro dissolution studies of the sustained 
release matrix tablets of Atenolol were performed using USP 
type II dissolution apparatus (paddle) at 50 rpm. The study 
was performed for 12 hours, and percentage drug release 
was calculated at 1 hours time intervals. The drug release 
profile were characterized by an initial burst effect (more 
than 18% drug release in 1 hrs) followed by a sustained 
release thereafter. The formulation F-2 contained chitosan 
which might have sustained the release since it is also known 
for its polymeric sustaining effect. The formulation F-2 gave 
89.57±0.24% of the drug release in 12 hrs of study. This is in 
fact true for the polymeric tablets since the surface drug 
gives a burst effect thereby releasing a amount of drug at 
once and since polymer like chitosan and HPMC  are present 
which provide matrix to the tablet, the further release is 
sustained. The drug release also resembles a higuchi pattern 
which indicates sustained drug release from the matrix 
tablets. This is again due to the presence of the polymer like 
chitosan and HPMC. 
6. SUMMARY & CONCLUSION 
Matrix tablets of Atenolol were prepared utilizing natural 
polymer chitosan. The tablets represented sustained drug 
release which is required for the drugs like Atenolol with low 
bioavailability and low half life. The tablets can sustain the 
drug release which can overcome such problems. Moreover 
the tablets contain chitosan which also is a permeability 
enhancer and hence could be utilized to increase the 
permeability of the drugs like Atenolol with very low 
permeability. The tablets possess high potential for being 
developed as sustained release dosage forms for drugs with 
low permeability, bioavailability and lower half life. 
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